Vanguard Group Inc. lessened its holdings in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) by 13.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,418,874 shares of the biopharmaceutical company’s stock after selling 219,915 shares during the quarter. Vanguard Group Inc. owned 2.78% of Tetraphase Pharmaceuticals worth $10,117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in TTPH. Dimensional Fund Advisors LP grew its stake in Tetraphase Pharmaceuticals by 180.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 408,078 shares during the period. Morgan Stanley lifted its position in shares of Tetraphase Pharmaceuticals by 112.1% during the 1st quarter. Morgan Stanley now owns 317,717 shares of the biopharmaceutical company’s stock valued at $2,919,000 after buying an additional 167,919 shares during the last quarter. Strs Ohio purchased a new position in shares of Tetraphase Pharmaceuticals during the 2nd quarter valued at $577,000. Geode Capital Management LLC lifted its position in shares of Tetraphase Pharmaceuticals by 17.0% during the 1st quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock valued at $2,880,000 after buying an additional 45,554 shares during the last quarter. Finally, Federated Investors Inc. PA lifted its position in shares of Tetraphase Pharmaceuticals by 25.1% during the 2nd quarter. Federated Investors Inc. PA now owns 206,574 shares of the biopharmaceutical company’s stock valued at $1,473,000 after buying an additional 41,384 shares during the last quarter. Hedge funds and other institutional investors own 47.40% of the company’s stock.

Tetraphase Pharmaceuticals, Inc. (TTPH) opened at $6.69 on Thursday. Tetraphase Pharmaceuticals, Inc. has a 1 year low of $3.57 and a 1 year high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). The business had revenue of $4.10 million for the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm’s quarterly revenue was up 355.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.58) EPS. sell-side analysts expect that Tetraphase Pharmaceuticals, Inc. will post -2.88 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Tetraphase Pharmaceuticals, Inc. (TTPH) Holdings Cut by Vanguard Group Inc.” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/tetraphase-pharmaceuticals-inc-ttph-holdings-cut-by-vanguard-group-inc/1721055.html.

In related news, insider Jacques Dumas sold 8,750 shares of the stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total transaction of $52,762.50. Following the sale, the insider now owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.50% of the company’s stock.

TTPH has been the topic of a number of recent research reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. Piper Jaffray Companies initiated coverage on Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They set an “overweight” rating and a $14.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $13.00 price target (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, July 26th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, October 28th. Finally, ValuEngine cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $15.15.

Tetraphase Pharmaceuticals Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Want to see what other hedge funds are holding TTPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH).

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.